gilead – Lab DB

Pharmaceutical R&D

Gilead Acquires Antibody-Drug Conjugate Pioneer Tubulis for Up to $5 Billion, Bolstering Oncology Pipeline

Teuku Ryan Apr 7, 2026 0

Sixteen months after forging a strategic collaboration, Gilead Sciences has announced its definitive agreement to acquire German biotechnology firm Tubulis,…

Gilead Sciences to Acquire Ouro Medicines for $2.2 Billion, Ushering in New Era of T-Cell Engagers in Autoimmune Diseases

Teuku Ryan Mar 24, 2026 0

Gilead Sciences is poised to make a significant entry into the burgeoning field of T-cell engagers (TCEs) with its $2.2…

Gilead Executive Sounds Alarm on Limited Innovation Investment Hindering Access to Advanced Therapies

Teuku Ryan Mar 20, 2026 0

The Netherlands faces significant challenges in ensuring timely patient access to life-changing advanced therapy medicinal products (ATMPs), a situation exacerbated…

Gilead Acquires Antibody-Drug Conjugate Pioneer Tubulis for Up to $5 Billion, Bolstering Oncology Pipeline

Gilead Sciences to Acquire Ouro Medicines for $2.2 Billion, Ushering in New Era of T-Cell Engagers in Autoimmune Diseases

Gilead Executive Sounds Alarm on Limited Innovation Investment Hindering Access to Advanced Therapies

YOU MAY HAVE MISSED

Breakthrough in Male Contraception: Cornell Scientists Identify Nonhormonal Pathway to Reversible Infertility via Meiotic Interruption

The Quest for Monoclonality: Sartorius Infographic Illuminates Next-Generation Solutions for Cell-Line Development

Immuto Scientific Pioneers AI-Enhanced Mass Spectrometry for Unprecedented Protein Structure Throughput

Mental Sharpness and Daily Productivity Gains Quantified in New University of Toronto Study